Literature DB >> 16189528

Natalizumab and PML.

Richard M Ransohoff.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16189528     DOI： 10.1038/nn1005-1275

Source DB:  PubMed          Journal:  Nat Neurosci        ISSN： 1097-6256            Impact factor:   24.884


× No keyword cloud information.
  38 in total

Review 1.  Progressive multifocal leukoencephalopathy: clinical and molecular aspects.

Authors:  Eleonora Tavazzi; Martyn K White; Kamel Khalili
Journal:  Rev Med Virol       Date:  2011-09-21       Impact factor: 6.989

Review 2.  Essential roles of VLA-4 in the hematopoietic system.

Authors:  Yoichi Imai; Motomu Shimaoka; Mineo Kurokawa
Journal:  Int J Hematol       Date:  2010-03-30       Impact factor: 2.490

3.  Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations.

Authors:  H Wiendl; K V Toyka; P Rieckmann; R Gold; H-P Hartung; R Hohlfeld
Journal:  J Neurol       Date:  2008-10-29       Impact factor: 4.849

4.  Therapy: Targeted but not trouble-free: efalizumab and PML.

Authors:  Eamonn S Molloy; Leonard H Calabrese
Journal:  Nat Rev Rheumatol       Date:  2009-08       Impact factor: 20.543

Review 5.  Infection risk in patients on multiple sclerosis therapeutics.

Authors:  Eric M Williamson; Joseph R Berger
Journal:  CNS Drugs       Date:  2015-03       Impact factor: 5.749

6.  Treating MS: getting to know the two birds in the bush.

Authors:  Terri M Laufer; Gregory F Wu
Journal:  J Clin Invest       Date:  2009-07       Impact factor: 14.808

7.  Rearrangement of the JC virus regulatory region sequence in the bone marrow of a patient with rheumatoid arthritis and progressive multifocal leukoencephalopathy.

Authors:  Angela Marzocchetti; Christian Wuthrich; Chen S Tan; Troy Tompkins; Francisco Bernal-Cano; Parul Bhargava; Allan H Ropper; Igor J Koralnik
Journal:  J Neurovirol       Date:  2008-11-06       Impact factor: 2.643

8.  Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function.

Authors:  B O Khatri; S Man; G Giovannoni; A P Koo; J-C Lee; B Tucky; F Lynn; S Jurgensen; J Woodworth; S Goelz; P W Duda; M A Panzara; R M Ransohoff; R J Fox
Journal:  Neurology       Date:  2009-02-03       Impact factor: 9.910

9.  Targeted delivery of complexes of biotin-PEG-polyethylenimine and NF-kappaB decoys to brain-derived endothelial cells in vitro.

Authors:  Raktima Bhattacharya; Berit Osburg; Dagmar Fischer; Ulrich Bickel
Journal:  Pharm Res       Date:  2007-10-20       Impact factor: 4.200

10.  Targeted inhibition of complement using complement receptor 2-conjugated inhibitors attenuates EAE.

Authors:  Xianzhen Hu; Stephen Tomlinson; Scott R Barnum
Journal:  Neurosci Lett       Date:  2012-10-16       Impact factor: 3.046
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.